🇺🇸 FDA

Intelligence Platform

Patents

Browse 14 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12351644

Anti-CD73 antibodies

Corvus Pharmaceuticals, Inc. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12174192

Methods for detecting and treating cancers having adenosine pathway activation

Corvus Pharmaceuticals, Inc. · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12116635

Methods for detecting and treating cancers having adenosine pathway activation

Corvus Pharmaceuticals, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12023337

Methods of treating cancer

Corvus Pharmaceuticals, Inc. · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11897874

Compounds and methods for modulating Interleukin-2-inducible T-cell kinase

Corvus Pharmaceuticals, Inc. · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11859007

Humanized anti-CD73 antibodies

Corvus Pharmaceuticals, Inc. · Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11266649

Pharmaceutical formulations

Corvus Pharmaceuticals, Inc. · Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11254686

Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor

Corvus Pharmaceuticals, Inc. · Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11040040

Methods of treating cancer

Corvus Pharmaceuticals, Inc. · Granted Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11008314

Compounds and methods for modulating interleukin-2-inducible t-cell kinase

Corvus Pharmaceuticals, Inc. · Granted Tue May 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10912776

Methods of treating cancer

Corvus Pharmaceuticals, Inc. · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10870652

Compounds and methods for modulating bruton's tyrosine kinase

Corvus Pharmaceuticals, Inc. · Granted Tue Dec 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10822426

Humanized anti-CD73 antibodies

Corvus Pharmaceuticals, Inc. · Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10793636

Anti-CD73 antibodies

Corvus Pharmaceuticals, Inc. · Granted Tue Oct 06 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted